BTW, full results of the ARBITER-HALTS 6 study will be presented Monday, November 16, 2009 at the AHA meeting, discussant - John J Kastelein. Most analysts and scientists think the trial was halted because Niaspan outperformed Zetia.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.